Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Turning Point Therapeutics (NASDAQ: TPTX) announced that CEO Athena Countouriotis will participate in two major healthcare conferences. She is set to join the Guggenheim Healthcare Talks 2022 Oncology Day on February 9 at 2 p.m. ET and the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at noon ET. Both sessions will be available via webcast on the company's Investors page. Turning Point focuses on precision oncology, with its leading drug candidate, repotrectinib, targeting key genetic drivers in cancers, currently being evaluated in several clinical trials.
- None.
- None.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Guggenheim Healthcare Talks 2022 Oncology Day on February 9 and the 11th Annual SVB Leerink Global Healthcare Conference on February 16.
Dr. Countouriotis is scheduled to participate in fireside chats at 2 p.m. ET p.m. on February 9 and at noon ET on February 16. Both sessions will be accessible via webcast through the Investors page of www.tptherapeutics.com.
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point Therapeutics’ business and the other risks described in Turning Point Therapeutics’ filings with the Securities and Exchange Commission (SEC), including its quarterly report on Form 10-Q filed with the SEC on November 9, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Adam Levy
ir@tptherapeutics.com
858-867-6366
FAQ
What events will Turning Point Therapeutics participate in February 2022?
What is the schedule for Athena Countouriotis's presentations?
How can investors access Turning Point Therapeutics' presentations?
What is the main focus of Turning Point Therapeutics?
What is repotrectinib and its significance?
